Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rademikibart in Chronic Rhinosinusitis with Nasal Polyps
NCT04783389Phase 2Terminated
- Sponsor
- Connect Biopharma
- Start
- Jun 2021
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of rademikibart in chronic rhinosinusitis with nasal polyps (CRSwNP) (3 arms), sponsored by Connect Biopharma. Primary endpoints: Change in Endoscopic Nasal Polyp Score at 24 weeks and Change in Average Daily Nasal Congestion Score at 24 weeks. Started Jun 2021; status: terminated.
02
Drugs
rademikibart
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT04783389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04783389.